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ORIGINAL ARTICLE
Does Immunotherapy of Viral Warts Provide Beneficial 
Effects When It Is Combined with Conventional 
Therapy?
Jae Woo Choi, M.D., Soyun Cho, M.D., Jong Hee Lee, M.D.
Department of Dermatology, Seoul National University Boramae Hospital, Seoul, Korea
Background: Cryotherapy has been accepted as the mainstay 
in treating periunugal and palmoplantar warts. The major 
drawback of cryotherapy is the requirement of several 
unbearably painful treatment sessions. Objective: This study 
aims to assess the efficacy of immunotherapy in viral wart 
treatment, as an adjunctive method to cryotherapy. 
Methods: Retrospective chart review was performed on 124 
patients visiting the hospital from January to December 2009 
for the treatment of periungual and plantar warts. We 
analyzed the number of cryotherapy sessions necessary for 
treating warts and assessed the clinical benefits from the 
addition of other treatment modalities, by adjusting the 
various confounding factors. Results: Of the 124 investigated 
patients, immunotherapy with diphenylcyclopropenone 
(DPCP) was performed in 14 patients (11%), together with 
cryotherapy. After adjusting the factors related to the 
therapeutic difficulties of wart, the average number of 
cryotherapy sessions for the immunotherapy-combined 
group was significantly lower (3.58±1.25) than that for the 
cryotherapy only group (5.10±0.44) (p=0.026). However, 
there were no differences in the number of treatment 
sessions of cryotherapy when topical 5-FU/salicylic acid 
agents were added to the treatment. Conclusion: Immuno-
therapy may be a successful adjuvant to cryotherapy in 
reducing the number of agonizing cryotherapy sessions. 
(Ann Dermatol 23(3) 282∼287, 2011)
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INTRODUCTION
Warts are common dermatologic disorders which are 
mediated by the human papilloma virus (HPV). They 
usually affect the children and adolescents, and some 
studies report that up to 10% of the young population has 
warts. Some warts may spontaneously disappear, while 
others persist and can spread on other body sites, 
provoking physical and emotional distress to the patients
1.
The current therapeutic options for warts include cry-
otherapy, eletrocauterization, surgical excision, laser 
ablation, bleomycin intralesional injection, topical agents, 
such as 5FU/salicylic acid, and immunotherapy. They 
work for the treatment of warts by direct destruction 
and/or induction of immunologic responses to virus- 
affected-keratinocytes. Some agents have intrinsic anti- 
viral activity
2. Clinicians should select, from this large 
array of therapeutic options, the best treatment option 
suitable for individual cases, considering the patients’ age, 
sex, previous medical history and the clinical charac-
teristics of the warts.
Cryotherapy using liquid nitrogen plays a crucial role in 
treating warts, especially those located on the periungual 
and palmopalantar areas
3-5. In clinical everyday practices, 
the treatment of these warts usually begins with cry-
otherapy. However, it can induce pain and even damage 
the patient’s skin by frostbite lesions around the treated 
area, albeit infrequently.Immunotherapy Along with Cryo-destruction Works Better on Warts
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Some pain sensitive patients may even give up the therapy 
before the end, therefore pain limits the success of 
cryotherapy
4.
Many wart patients have been reported with defective 
cell-mediated immune mechanisms, especially those 
showing multiple warts. Diverse immunomodulators, such 
as dinitrochlorobenzene (DNCB), squaric acid dibutylester 
(SADBE), and diphencyclopropenone (DPCP), have been 
used for treating warts
6. Among them, DPCP is the most 
widely used for its outstanding safety
7. Several topical 
agents containing 5FU, which interferes with the 
metabolic process of the nucleic acid in HPV are also 
widely used
8. Some agents enhance their antiviral efficacy 
by mixing keratolytic materials, such as formic acid or 
salicylic acid. Immunotherapy and topical agents have 
their own clinical advantage over other destructive 
treatment modalities. Several clinical studies focused on 
comparing various treatment modalities
9,10. However, 
little was verified about the combined therapy, especially 
cryotherapy combined with the ancillary methods.
This study was designed to evaluate the strength of 
commonly-used treatment modalities, and aimed at 
reducing the required number of painful cryotherapy 
sessions.
MATERIALS AND METHODS
Participants
Charts were reviewed retrospectively in 124 patients who 
visited our dermatologic clinic from January to December 
2009 for the treatment of periungual and plantar warts. 
This study included the patients who presented with warts 
on the periungual and/or palmoplantar areas, and receiv-
ed at least one session of cryotherapy. The types and 
sessions of treatment for every patient, as well as informa-
tion about age, sex, number and location of the wart 
lesions, were identified.
Treatment design
Cryotherapy with liquid nitrogen spray was generally 
applied every 3 or 4 weeks. Cryogen was applied 
perpendicularly to the wart at a distance of about 2 cm. 
The wart was sprayed until the ice-ball forming from the 
lesion center spread to a 2 mm margin of the lesion. The 
spraying time depended on the treated area. The regimen 
of 3 complete cycles of freezing, followed by 10 seconds 
thawing, was used. If the lesion was covered with heavy 
scales, they were gently peeled off with sterile blade by 
the clinician, before cryogen application.
For patients who received immunotherapy concurrently 
with cryotherpy, 0.1% DPCP was applied by the phy-
sician with the tape occlusion to the inner side of the 
upper arm, for 48 hours. After the desirable sensitization 
reaction of visible erythema was obtained on the site, 
patients were instructed to apply 1×10
−3%∼1×10
−2% 
of DPCP onto warts daily to potentiate more specific local 
immune reaction against the HPV affected keratinocytes.
5FU/salicylic acid is the primary topical agent prescribed 
for warts in our clinic. When the crust after cryotherapy 
came off naturally with the topical antibiotics, the patients 
were recommended to use 5FU/salicylic acid on the warts 
on a daily basis.
At every visit, the clinical improvement was checked and 
marked. When no single wart lesion was found by the 
clinical inspection with the help of magnifying lens, the 
patients were considered cured. The total treatment period 
was the time from the first visit to the endpoint of 
treatment. Every treatment modality was summarized, 
including the number of cryotherapy and bleomycin 
injection sessions, as well as the information whether the 
immunotherapy or topical agents were applied to patients. 
Patients who, in addition to cryotherapy, received DPCP 
application and experienced successful sensitization were 
included in the immunotherapy group, whereas those 
who had ever used 5FU/salicylic acid were included in 
the topical agent group.
Statistical analysis
The t-test was performed to compare the number of 
cryotherapy sessions required for clearing out every single 
wart, between the patients treated with cryotherapy and 
additional modalities (i.e. the combined therapy group) 
and those treated only with cryotherapy (i.e. the cry-
otherapy only group). Cryotherapy was the mainstay of 
treatment in this study; the combined therapy group 
included the immunotherapy group (i.e. DPCP sensitiza-
tion was successfully achieved), and the topical agent 
group (i.e. 5FU/salicylic acid was recommended). This 
was a retrospective study using the chart review. There-
fore, several confounders could bias the results. To 
minimize the unwanted bias, we chose the analysis of 
covariant (ANCOVA) for controlling the confounders. 
Statistical analyses were done with the appropriate 
procedures, as applicable. The statistical significance was 
set at the 0.05 level and the confidence interval at 95%. 
Data were analyzed with the SPSS software package 
Version 12.0 (SPSS Inc., Chicago, IL, USA).
RESULTS
Demographic analysis
Of 124 investigated patients, 60 were male and 64 were JW Choi, et al
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Fig. 1. The required number of cryotherapy sessions for complete
remission of warts. Before adjusting the confounders, patients 
treated with the combined method paradoxically required more
sessions, although the difference was not statistically significant.
However, after adjustment, the combined therapy significantly 
decreased the number of cryotherapy sessions. Data are 
presented as mean±SEM (*p＜0.05). Statistical significance was
determined using the Student’s t-test and adjustment was done 
by ANCOVA. DPCP: diphencyclopropenone.
Table 1. Demographic characteristics in the treatment groups
Total ＋Immunotherapy ＋5FU/
Salicylic acid
Age (years) 21.2±14.3 18.3±10.0 20.9±11.9
p-value 0.415 0.864
Sex (M/F) 60/64 9/5 25/24
p-value 0.326 0.914
Age and sex distribution between different therapeutic groups
is shown here. Each p-value stands for the statistical significance
level of the difference between the group that utilized the 
specific modality and the rest of the sample. For instance, the
mean age of the group that received the combined therapy of
cryotherapy and immunotherapy is 18.3 years old, and shows 
no statistically significant deviation from that of the patients who
did not receive immunotherapy. Statistical evaluation was 
performed with the Student’s t-test (p-value＜0.05). M: male, F:
female. 5FU: 5-Fluorouracil.
Table 2. Comparison of the required number of cryotherapy sessions, according to adoption of the concurrent immunotherapy
Before adjust After adjust
Cryotherapy sessions (times) Warts (lesions)  Period of treatment (months) Cryotherapy sessions (times)
Without DPCP 4.84±3.75 2.78±2.22 4.98±3.56 5.10±0.44
With DPCP 5.64±3.62 4.14±2.41 7.93±5.22 3.58±1.25
p-value 0.4 0.03* 0.05* 0.02*
Before adjusting for confounders (i.e. the number of wartsand the total treatment period), the patients who were also treated with
immunotherapy paradoxically required more sessions of cryotherapy, but the difference was not statistically significant. After adjustment, 
the combined therapeutic group needed far less cryotherapy sessions (mean 3.58), compared with those without immunotherapy (mean
5.10) The adjustment was done with ANCOVA (*p-value＜0.05). DPCP: diphencyclopropenone.
female. Immunotherapy using DPCP (14 cases), and 
treatment with 5FU/salicylic acid topical agent (49 cases) 
was conducted concurrently with cryotherapy, while the 
rest of the patients reveived cryotherapy alone. Among 14 
patients in the immunotherapy group, 9 patients were 
male and 5 patients were female. The topical agent group 
included almost the same number of male and female 
patients (i.e. 25 male and 24 female). The average age was 
21.2±14.3 years for total patients, 18.3±10.0 for the 
immunotherapy group, and 20.9±11.9 for the topical 
agent group. No statistically significant differences were 
found in gender ratio and average age between the 
investigated groups (Table 1).
Immunotherapy combined with cryotherapy (The im-
munotherapy group)
To achieve clinical resolution, the patients were treated on 
average 4.84±3.75 times with cryotherapy and cryothe-
rapy was applied 5.64±3.62 times in the immunotherapy 
group. The number of treatment sessions did not show 
any statistically significant differences (p=0.4) (Table 2). 
The mean number of warts was 2.78±2.22 in the cry-
otherapy alone group and 4.14±2.41 in the immuno-
therapy group. The mean period of treatment was 
4.98±3.56 months in the cryotherapy alone group, and 
7.93±5.22 months in the immunotherapy group. Both 
number of warts and total treatment period were 
significantly higher in the immunotherapy group than in 
the cryotherapy alone group (p=0.03 and 0.05 res-
pectively) (Table 2). Generally speaking, more wart les-
ions and longer treatment periods imply higher thera-
peutic difficulties. Thus, it can be suggested that the 
addition of immunotherapy to cryotherapy was more 
likely in severe wart cases. To eliminate the bias produced 
by these confounders, the ANCOVA test was conducted, 
with the number of lesions and the treatment period as 
covariants. After adjustment, the number of cryotherapy 
sessions required for cure was 5.10±0.44 for the cry-
otherapy alone group, and 3.58±1.25 for the immuno-Immunotherapy Along with Cryo-destruction Works Better on Warts
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Table 3. Comparison of the required number of cryotherapy sessions, according to adoption of the concurrent topical agent
Before adjust After adjust
Cryotherapy 
sessions (times) Warts (lesions)  Period of 
treatment (months)
Cryotherapy 
sessions (times)
Without 5FU/Salicylic acid 4.03±2.53 2.61±2.16 4.12±2.84 5.01±0.55
With 5FU/Salicylic acid 6.31±4.75 3.43±2.36 7.14±4.51 4.80±0.69
p-value 0.003* 0.05* ＜0.001* 0.6
Before adjustment, the patients who applied 5FU/Salicylic acid with cryotherapy paradoxically required more cryotherapy sessions
(mean 6.31) than the rest of the sample (mean 4.03). After adjusting for confounders, there was no statistical difference in the mean
number of cryotherapy sessions between the investigated groups (*p-value＜0.05). 5FU: 5-Fluorouracil.
therapy group (p=0.026) (Fig. 1).
5FU/Salicylic acid topical treatment combined with 
cryotherapy (The topical agent group)
The number of warts was higher in the topical agent group 
(2.61±2.16 vs 3.43±2.36, p=0.05) and the longer 
treatment period was noticed in the topical agent group, 
as well (4.12±2.84 months vs 7.14±4.51 months p= 
0.000). Adjusting the number of lesions and the treatment 
period, the number of cryotherapy sessions was 5.01± 
0.55 for the cryotherapy alone group and 4.80±0.69 for 
the topical agent group. However, the difference was not 
statistically significant (p=0.6) (Table 3).
DISCUSSION
Cryotherapy using liquid nitrogen is a widely adopted 
dermatologic treatment for curing warts, and it is usually 
chosen as the first line therapy in warts
11. The success rate 
is variable depending on the reports. However, over 70% 
of cure rate was guaranteed by several clinical trials
9,12. 
Cryotherapy can directly destroy the viral affected kera-
tinocytes
13, and can also trigger the immunologic reaction 
causing secondary cell damage
14.
As cryotherapy is usually done at several weeks intervals, 
the patients are not bothered by frequent visits to the 
clinic, as previously shown
14. It is conveniently performed 
using a spray, as well as cotton balls, and is only 
performed by clinicians. Thus, it assures more exact 
treatment, compared with other modalities, such as 
topical agents which are applied by patients themselves. 
However, severe pain around the treated area is often 
unbearable, especially when the lesion is located in the 
highly innervated distal ends of the limbs, such as the 
periungium and palmoplantar areas. This modality defin-
itely needs several sessions to eradicate warts and 
clinicians should exert every effort to reduce the number 
of agonizing treatment sessions. Some clinicians have 
tried to lower the discomfort by applying topical anes-
thetic agents before shooting the cryogen; however, it 
requires additional time and does not warrant a complete 
pain-free procedure
15.
DNCB was initially used as an immunomodulating agent. 
As its major side effects such as teratogenesis and 
carcinogenesis were revealed, it is now replaced by a 
safer topical agent, i.e. DPCP
16. Immunotherapy is 
particularly helpful for patients with multiple warts, 
because it stirs up specific as well as non-specific 
inflammation in the whole body, eradicating all warts 
simultaneously
17. Previously Orecchia et al. reported 
successful treatment results in multiple recalcitrant warts 
by weekly application of DPCP for fifteen weeks. Among 
44 patients, 20 patients were completely cured and 17 
were improved, with reduced number and size of warts
6. 
Aghaei also conducted a similar clinical trial to evaluate 
the efficacy of immunotherapy, and found that four out of 
six patients achieved complete clearance in twelve weeks, 
while the remaining two only exhibited slight improve-
ment
18. According to previous reports, immunotherapy 
showed clear clinical benefits in the treatment of warts. 
However, this treatment is generally the second choice 
method, and is particularly used in refractory warts which 
are unresponsive to cryotherapy. Immunotherapy might 
produce minor rash or pruritus at the site of application. 
However, the discomfort for patients is far less than those 
of cryotherapy and bleomycin injections. Nevertheless, it 
requires frequent, weekly visits to the clinic and might 
therefore take more time to eradicate warts
6.
In many clinics, it is a common practice to combine 
immunotherapy and/or topical agents with cryotherapy. 
Unexpectedly, the previous reports on cryotherapy 
combined with either podophyllin cream or 5FU showed 
no increment in the curing rate, compared with cry-
otherapy alone
19,20. No specific explanations about the 
disappointing outcomes of topical agents were provided 
in both previous studies, and the authors just suggested JW Choi, et al
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that the insufficient sample size might be a reason.
In this study, the retrospective chart review revealed no 
meaningful decrease in the number of cryotherapy 
sessions in the immunotherapy group, and, at first, there 
was even a paradoxical increase in the topical agent 
group, compared with the cryotherapy alone group. 
Multiple and deep-seated warts were usually treated with 
combined therapy and the simple chart review did not 
count for it. In general, the patients with more difficult 
warts are more likely to receive additional therapy. 
Multiplicity and the total treatment period were thought to 
reflect the therapeutic difficulties
21. To take into account 
the therapeutic difficulties, such as the number of lesions 
and the treatment period, covariant analysis was per-
formed in this study. Thus, we found that the number of 
cryotherapy sessions decreased significantly in the immu-
notherapy group, while there were no differences in the 
topical agent group, compared with cryotherapy alone 
group. The discordant results between immunotherapy 
and topical agents might be explained by the fact that 
immunotherapy produces more damage to the viral 
affected cells by triggering the systemic inflammatory 
reaction and by the fact that it is generally done much 
precisely by clinicians, while the topical treatment is 
carried out by the patients themselves. Daily application 
of 5FU/Salicylic acid might be irritating or the patients 
may simply forget to do it. This result supports results from 
previous studies demonstrating no clinical benefit of 
topical agents, when associated with cryotherapy
19,20.
Cryotherapy techniques differ between practitioners with 
regard to freezing/thawing time, mode of application (i.e. 
cryogen spray versus cotton ball application) and treat-
ment intervals
2. When the spray gun is used, it is held 
perpendicular to the wart at a distance of 1∼2 cm and 
liquid nitrogen is sprayed until the ice ball has spread 
from the center to include the edge of the wart and a 2 
mm margin
21. The lesion is then allowed to thaw. The 
thawing time depends on complete disappearance of the 
ice ball. From accumulated experience of cryotherapy 
conducted in our clinic, the ice ball disappears completely 
in less than 10 seconds. To minimize variation of the 
treatment results, we applied this procedure of freezing 
(i.e. the nitrogen gun) and 10 seconds of thawing.
This retrospective research bears the limitations that every 
confounder was not completely controlled and that the 
size of the combined therapy group was not sufficient. 
However, we propose that the combination of cry-
otherapy with immunotherapy could be very helpful, as it 
reduces the number of required sessions of this painful 
procedure. As the pain hinders the wart treatment and 
lowers the success rate, the clinicians can achieve 
desirable treatment outcomes with concurrent DPCP 
immunotherapy, by reducing the number of painful 
cryotherapy sessions and also by raising the patients’ 
compliance.
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